Ocrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmts

被引：0

作者：

Wiendl, H. ^{[1
]}

Comi, G. ^{[2
]}

Oreja-Guevara, C. ^{[3
]}

Siva, A. ^{[4
]}

Van Wijmeersch, B. ^{[5
,6
]}

Wuerfel, J. ^{[7
,8
]}

Buffels, R. ^{[9
]}

Kadner, K. ^{[9
]}

Kuenzel, T. ^{[9
]}

Vermersch, P. ^{[10
]}

机构：

[1] Univ Munster, Munster, Germany

[2] Univ Vita Salute San Raffaele, Milan, Italy

[3] Hosp Clin San Carlos, Madrid, Spain

[4] Istanbul Univ, Cerrahpasa Sch Med, Istanbul, Turkey

[5] Hasselt Univ, Pelt, Belgium

[6] Rehabil & MS Ctr Pelt, Pelt, Belgium

[7] Univ Basel, Med Image Anal Ctr MIAC AG, Basel, Switzerland

[8] Univ Basel, Dept Biomed Engn, Basel, Switzerland

[9] F Hoffmann La Roche Ltd, Basel, Switzerland

[10] Univ Lille, Lille, France

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P0219

引用

页码：224 / 225

页数：2